coronaviru
outbreak
late
compris
seriou
like
pandem
threat
worldwid
given
diseas
approv
vaccin
drug
effort
drug
design
clinic
trail
old
drug
base
mechan
action
worthi
credit
circumst
experienc
dock
experi
use
newli
releas
coordin
structur
proteas
receptor
thought
select
chemic
among
antivir
antibiot
drug
ligand
may
lead
context
select
nine
drug
proteas
inhibitor
twentyon
candid
anti
bronchiti
drug
base
chemic
structur
enrol
blind
activ
sitedirect
dock
differ
mode
nativelik
condit
interact
find
suggest
bind
capac
inhibitori
potenc
candid
follow
proteas
inhibitor
anti
bronchiti
medicin
drug
bioavail
hydrophob
hydrophob
properti
bind
site
also
rate
metabol
deactiv
human
bodi
next
determin
overal
effect
viral
infect
net
result
survey
clinic
trial
assess
therapeut
use
coronaviru
infect
outbreak
coronaviru
caus
sever
acut
respiratori
syndrom
corona
viru
positivesens
singlestrand
rna
viru
caus
total
report
case
februari
china
increas
risk
world
wide
spread
compris
seriou
lifethreaten
issu
human
safeti
fever
cough
short
breath
main
symptom
diseas
may
lead
eventu
pneumonia
mortal
rate
current
approv
drug
coronaviru
infecti
even
though
antivir
drug
inhibitor
proteas
integras
polymeras
enzym
design
advanc
studi
among
inhibitor
antiproteas
inhibitor
seem
act
effect
block
viru
replic
provid
promis
treatment
sar
mer
diseas
given
proteas
vital
role
viru
life
cycl
matur
via
function
protein
product
precursor
seem
good
target
drug
design
viral
infect
infect
well
base
data
avail
pubm
databas
http
wwwncbinlmnihgovpubm
proteas
ec
protein
residu
contrast
sar
proteas
amino
acid
residu
sequenc
align
use
emboss
stretcher
server
wwwebiacuk
revil
corona
proteas
compar
sar
proteas
contain
one
amino
acid
delet
posit
cy
well
mutat
along
sequenc
stretch
depict
scheme
chang
proteas
sequenc
may
lead
differ
global
architectur
protein
especi
bind
catalyt
site
way
local
bind
site
shift
neighbor
residu
contrast
sar
proteas
bind
site
survey
two
proteas
use
comput
atla
surfac
topographi
protein
http
stsbioeuiceducastp
server
confirm
chang
enzym
bind
site
tabl
repres
bind
site
residu
sar
proteas
evid
three
residu
similar
two
enzym
posit
differ
amino
acid
constitu
geometri
expectedli
need
differ
inhibitor
differ
stereochemistri
base
fact
necessari
search
differ
inhibitor
coronaviru
investig
main
topic
studi
next
step
carri
activ
sitedirect
dock
select
ligand
arguslab
softwar
studi
bind
capac
ligand
fit
activ
site
bind
energi
obtain
dock
blind
activ
sitedirect
experi
shown
tabl
pearson
twotail
test
correl
perform
blind
activ
sitedirect
dock
reveal
signific
correl
blind
sitedirect
energi
pvalu
mean
mechan
underli
interact
ligand
proteas
two
energi
complet
independ
variabl
could
sum
compar
purpos
figur
show
total
bind
energi
ligand
experi
base
find
clear
tipranavir
seem
potent
inhibitor
proteas
clinic
trial
reveal
tipranavir
capabl
virus
replic
patient
resist
proteas
inhibitor
resist
drug
need
multipl
mutat
take
place
simultan
proteas
gene
applic
drug
combin
one
antiretrovir
drug
ritonavir
approv
treatment
fda
second
effect
drug
introduc
cefditoren
cephalosporin
antibiot
broadspectrum
administ
differ
condit
pneumonia
acut
bacteri
chronic
bronchiti
indinavir
third
effect
inhibitor
candid
treatment
consid
miscellan
drug
avail
treatment
current
recommend
treatment
due
side
effect
howev
shown
indinavir
decreas
viral
replic
increas
life
expect
patient
sever
year
viral
infect
low
water
solubl
indinavir
requir
plenti
water
dink
prevent
precipit
crystal
kidney
atazanavir
forth
proteas
inhibitor
recommend
infect
inhibitor
structur
mimic
transit
state
proteolysi
phepro
cleavag
site
atazanavir
prescrib
treatment
conjunct
antiretrovir
drug
given
human
proteas
could
hydrolyz
phepro
bond
atazanavir
inhibit
human
proteas
eighth
drug
recommend
clinic
trial
ritonavir
known
inhibitor
proteas
inhibitor
rare
use
alon
infecti
instead
often
use
conjunct
proteas
inhibitor
boost
antivir
action
ritonavir
inhibit
liver
intestin
enzym
metabol
proteas
inhibitor
way
allow
lower
dose
drug
exert
effect
ninth
drug
seem
use
clinic
trial
erythromycin
well
known
safe
antibiot
respiratori
tract
infect
final
amprenavir
tenth
drug
recommend
clinic
trial
infect
vaccin
approv
drug
reason
rate
incid
increas
percent
mortal
result
indic
structur
differ
primari
structur
proteas
contrast
sar
lead
alter
enzym
bind
site
hypothes
alter
caus
enzym
respond
antisar
proteas
inhibitor
treatment
work
via
reexamin
proteas
inhibitor
differ
anti
bronchiti
antibiot
tri
find
effect
inhibitor
treatment
final
pick
follow
order
inhibitori
potenc
among
proteas
inhibitor
tipranavir
indinavir
atazanavir
darunavir
ritonavir
amprenavir
similarli
follow
order
anti
bronchiti
obtain
consid
fact
drug
use
studi
approv
fda
clinic
applic
hope
find
consid
clinic
trial
patient
overcom
world
wide
current
outbreak
coronaviru
